Ceresil Canon, 250 mg/ml 4 ml 5 pcs

Pharmacodynamics

Cyticoline is a natural endogenous compound which is an intermediate metabolite in the synthesis of phosphatidylcholine, one of the main structural components of the cell membrane. Citicoline, being a precursor of key ultrastructural components of the cell membrane (mainly phospholipids), has a broad spectrum of action: it promotes the restoration of damaged cell membranes, inhibits the action of phospholipases, prevents the excessive formation of free radicals and also prevents cell death by acting on apoptosis mechanisms. In the acute period of stroke citicoline reduces the volume of brain tissue damage, improves cholinergic transmission. In craniocerebral trauma reduces the duration of post-traumatic coma and severity of neurological symptoms, in addition, contributes to reducing the duration of the recovery period. In chronic cerebral hypoxia citicoline is effective in treating cognitive disorders such as memory impairment, lack of initiative, difficulties in daily activities and self-care. It increases the level of attention and consciousness and reduces the manifestation of amnesia.

Cyticoline is effective in the treatment of sensory and motor neurological disorders of degenerative and vascular etiology.

Pharmacokinetics

absorption

Cyticoline is well absorbed when taken orally. Absorption after oral administration is almost complete and bioavailability is about the same as after intravenous administration.

Distribution

Cyticoline is largely distributed in brain structures, with rapid incorporation of choline fractions into structural phospholipids and citidine fractions into citidine nucleotides and nucleic acids.

Cyticolin penetrates the brain and is actively incorporated into cellular, cytoplasmic and mitochondrial membranes, forming part of the structural phospholipid fraction.

Metabolism

The drug is metabolized in the intestine and in the liver to form choline and cytidine. After intake, plasma concentrations of choline are significantly increased.

Evacuation

Only 15% of the administered dose of citicoline is excreted from the human body: less than 3% by the kidneys and through the intestines and about 12% with exhaled CO2.

Two phases can be distinguished in the urinary excretion of citicoline: a first phase lasting about 36 hours, during which the excretion rate decreases rapidly, and a second phase, during which the excretion rate decreases much more slowly. The same is observed in exhaled CC2 – the excretion rate decreases rapidly after about 15 hours and then decreases at a much slower rate.

.

Indications

• Acute period of ischemic stroke (as part of complex therapy).
• Cerebral trauma (CTS), acute (as part of complex therapy) and recovery period.
• Cognitive and behavioral disorders in degenerative and vascular diseases of the brain.
  

Active ingredient

Citicoline

Composition

1 ml of the solution contains: